 SAN FRANCISCO, June 16, 2021 GLOBE NEWSWIRE -- FibroGen, Inc. NASDAQ: FGEN announced activation of an experimental arm in the Pancreatic Cancer Action Networks PanCAN Precision Promise SM adaptive trial platform evaluating pamrevlumab and standard of care for patients with metastatic pancreatic cancer. The objective of Precision Promise is to expedite the study and approval of promising therapies for pancreatic cancer by bringing multiple stakeholders together, including academic, industry and regulatory entities. 